Hypertensive patients with coronary artery disease had similar outcomes regardless of whether they took a β blocker or a calcium antagonist for primary control of their blood pressure.
Dr Carl Pepine of the University of Florida College of Medicine, Gainesville, and colleagues randomised 22 576 patients with hypertension and coronary artery disease 50 years and older to receive either sustained release verapamil or atenolol as first line treatment for their high blood pressure. The study enrolled patients from 862 sites in 14 countries from 1997 to 2003 (JAMA 2003;290: 2805-16).
The study, called the international verapamil-trandolapril study (INVEST), was intended to compare multidrug strategies rather than individual agents, as most hypertensive patients need more than one drug to control blood pressure adequately.
Patients enrolled in the study could receive additional treatment with either hydrochlorothiazide or trandolapril if the single, first line agent was unable to control their blood pressure adequately. Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment. Patients in the group being given a calcium antagonist were not allowed β blockers, however, and those in the β blocker group were not allowed calcium antagonists.
After an average follow up of 2.7 years for each patient, 2269 patients had had a primary outcome event—death, a non-fatal myocardial infarction, or a non-fatal stroke. There was no significant difference between the two groups (9.93% in the verapamil group and 10.17% in the atenolol group; relative risk 0.98 (95% confidence interval 0.90 to 1.06)).
The blood pressure goals of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure were achieved by 65% (for systolic pressure) and 88.5% (for diastolic) of the patients receiving the calcium channel blocker and by 64% (systolic) and 88.1% (diastolic) of the patients receiving treatment with atenolol.
A total of 72% of patients taking a calcium channel blocker and 71% of the patients taking a β blocker achieved a systolic blood pressure of <140 mm Hg and diastolic blood pressure of <90 mm Hg.
“The clinical equivalence of the CAS [calcium antagonist strategy] and NCAS [non-calcium antagonist strategy] groups in prevention of death, [heart attack], or stroke supports the use of either strategy in clinically stable patients with CAD [coronary artery disease] who require blood pressure control,” said Dr Pepine. “The decision regarding which drug classes to use in specific CAD patients should be based on additional factors including adverse experiences, history of heart failure, diabetes risk, and the physician's best judgment.”
